Why a Drug Works in One Rhythm but Not Another
Stop memorizing lists of drugs and rhythms. Start matching the specific biophysical properties of a drug to the specific vulnerabilities of an arrhythmia.
This is the culmination of our journey into pharmacology. We stop memorizing lists. We start matching the specific biophysical properties of a drug to the precise anatomical and biophysical vulnerabilities of an arrhythmia.
When an antiarrhythmic drug fails, it is usually because we treated the rhythm on the surface ECG rather than the underlying mechanism inside the cell. We handed a mechanic a wrench to fix a flat tire.
Let's look at four distinct clinical scenarios. We will ask what the circuit needs to survive, and we will watch how specific drugs dismantle those precise requirements.
AVNRT vs. Flecainide
A patient arrives with a narrow complex tachycardia at 180 beats per minute. You diagnose AVNRT, a micro-reentrant loop using the fast and slow pathways near the AV node.
You know the compact AV node is driven by calcium. You might expect a calcium channel blocker to be the only solution. Yet, you give Flecainide—a pure sodium channel blocker—and the rhythm terminates perfectly. Why?
The answer lies in the anatomy of the circuit. AVNRT uses nodal tissue, but the fast pathway in the upper atrium actually relies heavily on sodium current to conduct rapidly. The compact node is calcium-dependent, but the surrounding fast pathway is a hybrid.
By blocking sodium, Flecainide slows conduction specifically in the retrograde fast pathway. As the wave trudges up the slow pathway and tries to return down the fast one, the fast pathway is still recovering. The wavefront hits refractory tissue. The circuit breaks because it ran out of road.
Atrial Fibrillation vs. Beta-Blockers
Another patient is in rapid Atrial Fibrillation. You push Metoprolol, a beta-blocker. The heart rate slows beautifully from 140 down to 80, but the patient remains in Atrial Fibrillation. The rhythm didn't change at all.
Why doesn't a beta-blocker stop AFib?
Because AFib is driven by structural fragmentation, fibrosis, and angry automatic sparks firing from the pulmonary veins. A beta-blocker does absolutely nothing to the pulmonary veins. It has no effect on atrial fibrosis. It does not prolong the atrial refractory period.
The beta-blocker only acts on the AV node. It raises the tollbooth price. It prevents the rapid atrial impulses from reaching the ventricles. You have treated the rate. You have completely ignored the rhythm.
Scar VT vs. Amiodarone
A patient with a prior massive heart attack develops wide complex tachycardia. This is Scar VT. An electrical wavefront is spinning endlessly around a dead zone of collagen.
You give Amiodarone. Why is this the drug of choice for post-MI VT?
A scar circuit requires an excitable gap. The tissue directly in front of the wavefront must have finished repolarizing before the wave arrives. If the wave hits refractory tissue, it dies.
Amiodarone is a multi-tool. Its Class III property (blocking potassium channels) massively prolongs the action potential duration in the surrounding healthy muscle. It leaves the tissue refractory for longer, effectively closing the excitable gap.
Simultaneously, its Class I property (blocking sodium channels) slows conduction within the sick isthmus of the scar. Amiodarone attacks the circuit from both sides: it slows the wave down, and it builds a wall of refractoriness right in front of it.
Idiopathic VT vs. Verapamil
A 25-year-old with a structurally normal heart presents with VT. You diagnose Fascicular VT. You give Verapamil, a calcium channel blocker, and the rhythm terminates immediately.
But if you gave Verapamil to the previous patient with Scar VT, you could kill them. Why the profound difference?
Fascicular VT is a unique micro-reentrant loop spinning inside the healthy Purkinje system. For reasons we don't entirely understand, this specific fascicular tissue is highly sensitive to calcium entry. Blocking calcium breaks the circuit.
Scar VT is entirely different. It is driven by sodium channels desperately trying to fire in dying, depolarized myocardium. Calcium blockers do not touch the scar circuit. Instead, they crush the contractility of the remaining healthy muscle, plunging the patient with an already weak heart into cardiogenic shock.
Every antiarrhythmic drug is a proarrhythmic drug. When you alter the biophysics of the cell to fix one problem, you inevitably create the substrate for another.
Consider Sotalol. It blocks potassium channels to prolong the refractory period, beautifully stopping reentrant circuits by widening the refractory shield. But as we learned in Volume III, prolonging the plateau phase gives calcium channels time to recover and fire again, triggering Early Afterdepolarizations (EADs) and Torsades de Pointes. The drug that stopped the reentry set the stage for lethal triggered activity.
Consider Flecainide. It blocks sodium to slow conduction, terminating AFib. But if the patient goes into Atrial Flutter, the drug slows the flutter circuit just enough that the AV node can conduct every single beat. You turn a manageable 2:1 flutter into a deadly 1:1 flutter with a ventricular rate of 250 bpm.
Key Takeaways
- Target the Mechanism: Drug selection requires matching the biophysical vulnerability of the specific circuit to the cellular effect of the drug.
- Sodium and Conduction: Flecainide breaks AVNRT by selectively slowing the sodium-dependent retrograde fast pathway.
- Rate vs Rhythm: Beta-blockers do not terminate Atrial Fibrillation because they target AV nodal conduction, not the pulmonary vein triggers or atrial fibrosis.
- Closing the Gap: Amiodarone treats scar VT by attacking both requirements: slowing conduction (Class I) and closing the excitable gap via refractoriness (Class III).
- The Proarrhythmic Price: Altering cellular biophysics always risks new arrhythmias. Sotalol cures reentry but causes triggered activity; Flecainide cures AFib but can cause 1:1 flutter.